{
    "clinical_study": {
        "@rank": "109221", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "Rifamycin SV-MMX\u00ae 400 mg b.i.d."
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Experimental", 
                "description": "Rifamycin SV-MMX\u00ae 600 mg t.i.d."
            }, 
            {
                "arm_group_label": "C", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Rifamycin SV-MMX\u00ae placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the trial is to compare the efficacy of Rifamycin SV-MMX\u00ae 400 mg b.i.d. vs.\n      Rifamycin SV-MMX\u00ae 600 mg t.i.d. vs. placebo in patients with acute uncomplicated\n      diverticulitis."
        }, 
        "brief_title": "Rifamycin SV-MMX\u00ae 400 mg b.i.d. vs. Rifamycin SV-MMX\u00ae 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Uncomplicated Diverticulitis", 
        "condition_browse": {
            "mesh_term": "Diverticulitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed informed consent,\n\n          2. Patient is eligible for out-patient treatment,\n\n          3. Men or women between 18 and 80 years of age,\n\n          4. Diagnosis of left-sided uncomplicated diverticulitis confirmed by ultrasonography\n             (US) and/or computed tomography (CT) according to modified Hinchey classification\n             (stage 1a) or Hansen/Stock classification (stage I/IIa) or Ambrosetti classification\n             (stage mild),\n\n          5. Presence of significant left lower quadrant pain during the last 24 hours before\n             baseline,\n\n          6. CRP > ULN and/or leucocytosis (> ULN) at screening visit\n\n        Exclusion Criteria:\n\n          1. Existing complications of diverticulitis (diverticulitis with associated abscess,\n             fistula, obstruction or perforation),\n\n          2. Right-sided diverticulitis,\n\n          3. Previous colonic surgery (except appendectomy, haemorrhoidectomy, and endoscopic\n             removal of polyps),\n\n          4. Chronic inflammatory bowel disease (such as Crohn`s disease, ulcerative colitis) or\n             celiac disease,\n\n          5. Presence of symptomatic organic disease of the gastrointestinal tract (with the\n             exception of non-bleeding hemorrhoids or hiatal hernia),\n\n          6. Hemorrhagic diathesis,\n\n          7. Active peptic ulcer disease,\n\n          8. Abnormal hepatic function or liver cirrhosis,\n\n          9. Abnormal renal function,\n\n         10. Colorectal cancer or a history of colorectal cancer,"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "375", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847664", 
            "org_study_id": "RIT-4/DIV"
        }, 
        "intervention": {
            "arm_group_label": [
                "A", 
                "B"
            ], 
            "intervention_name": "Rifamycin SV-MMX\u00ae", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Rifamycins", 
                "Rifamycin SV"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "contact": {
                "email": "kruis@evkk.de", 
                "last_name": "Wolgang Kruis, Prof. Dr.", 
                "phone": "+49 (0)221 8289", 
                "phone_ext": "5289"
            }, 
            "facility": {
                "address": {
                    "city": "Cologne", 
                    "country": "Germany", 
                    "state": "Nordrhein-Westfalen", 
                    "zip": "51103"
                }, 
                "name": "Evangelisches Krankenhaus Kalk"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy of Oral Rifamycin SV-MMX\u00ae 400 mg b.i.d. vs. Rifamycin SV-MMX\u00ae 600 mg t.i.d. vs. Placebo in the Treatment of Acute Uncomplicated Diverticulitis", 
        "overall_contact": {
            "email": "nacak@drfalkpharma.de", 
            "last_name": "Tanju Nacak, Dr.", 
            "phone": "+49 (0)761 1514", 
            "phone_ext": "187"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Treatment success includes e.g.:\nabsence of diverticulitis related symptoms\nno complications of acute diverticulitis\nno hospitalisation due to acute diverticulitis", 
            "measure": "Rate of patients with treatment success at the day 10 visit", 
            "time_frame": "10 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847664"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "First visit with treatment success", 
                "time_frame": "10 days"
            }, 
            {
                "measure": "Rate of surgical intervention of acute diverticulitis", 
                "time_frame": "10 days"
            }, 
            {
                "measure": "Rate of hospitalisation due to acute diverticulitis", 
                "time_frame": "10 days"
            }, 
            {
                "measure": "Rate of occurrence of complicated diverticulitis", 
                "time_frame": "10 days"
            }
        ], 
        "source": "Dr. Falk Pharma GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dr. Falk Pharma GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}